Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
#Pharmacology #Semaglutide #GLP1 #DiabetesManagement #ObesityTreatment #PharmaEducation #ClinicalPharmacology #PharmaceuticalScience #DrugMechanism #HealthcareInnovation #PharmaStudents #MedicalScience Semaglutide: GLP-1 Receptor Agonist for Diabetes and Obesity "Semaglutide" Class GLP-1 Receptor Agonist (Glucagon-Like Peptide-1 analogue) Mechanism of Action (MOA) Mimics endogenous GLP-1 hormone Stimulates glucose-dependent insulin secretion from pancreatic -cells Suppresses glucagon release from -cells Delays gastric emptying prolonged satiety Acts on hypothalamic appetite centers reduced food intake Result: Improved glycemic control + significant weight reduction Approved Uses Type 2 Diabetes Mellitus improves glycemic control Chronic Weight Management (obesity / overweight with comorbidities) Reduction of cardiovascular risk in T2DM patients with established CVD Contraindications Personal or family history of Medullary Thyroid Carcinoma (MTC) Multiple Endocrine Neoplasia Syndrome type 2 (MEN2) Known hypersensitivity to semaglutide Caution in patients with history of pancreatitis Use in Pregnancy Not recommended during pregnancy Animal studies show potential fetal harm and weight-loss drugs are generally avoided in pregnancy
Insulin resistance is a metabolic condition in which the body's cells become less responsive to the hormone insulin, which is produced by the pancreas
Semaglutide/Tirzepatide may be prescribed for weight loss, if appropriate
The Rise of Tirzepatide While semaglutide (Ozempic) has been a well-known player in this category, tirzepatide (Mounjaro) emerged more recently, offering a dual mechanism of action
US$ 27.17
US$ 26.00
US$ 29.50
US$ 26.74
US$ 23.39
US$ 24.24
US$ 28.45
